PTIX Protagenic Therapeutics, Inc.\new
Pharmaceutical Preparations · OTC · SEC CIK 1022899 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY168.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA155.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets50.8%
Debt / equity0.00x
Current ratio0.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.30x
Accruals ratio201.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-09-30 | 2026Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q3*2025-12-31 | 2026Q2*2025-09-30 | 2026Q12025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $26,904 | $109,925 | $80,769 | $153,786 | $218,343 | $394,112 | $880,372 | $134,580 |
| SG&A expense | $64,491 | $97,980 | -$157,555 | $154,817 | $108,933 | $50,089 | $567,736 | $49,697 |
| Operating income | -$670,601 | -$961,247 | -$120,331 | -$925,103 | -$1.11M | -$1.21M | -$1.45M | -$401,401 |
| Pretax income | -$667,194 | -$963,616 | $5.08M | $2.21M | -$869,496 | -$5.06M | -$1.44M | -$850,287 |
| Net income | -$667,194 | -$963,616 | $5.08M | $2.21M | -$869,496 | -$5.06M | -$1.44M | -$850,287 |
| EBITDA | -$667,690 | -$952,935 | -$108,830 | -$912,531 | -$1.10M | -$1.20M | -$1.44M | -$401,401 |
| EPS (basic) | -0.37 | -0.53 | — | 1.14 | -0.47 | -1.37 | -2.75 | -0.16 |
| EPS (diluted) | -0.37 | -0.53 | — | 1.14 | -0.47 | -1.37 | -2.75 | -0.16 |
| Weighted avg. shares (diluted) | 1.81M | 1.81M | — | 1.93M | 1.85M | 3.70M | 523,185 | 5.40M |
| Banking | ||||||||
| Net interest income | $3,407 | $10,763 | -$1.31M | $23,831 | $34,337 | -$238,727 | -$351,740 | -$448,886 |
| Balance sheet | ||||||||
| Cash & equivalents | $76,909 | $565,985 | $1.51M | $2.21M | $2.72M | $4.10M | $14,531 | $79,568 |
| Inventory | — | — | — | $1,074 | $1,075 | $1,095 | $1,038 | — |
| Current assets | $188,464 | $709,871 | $1.54M | $2.30M | $2.86M | $4.33M | $89,093 | $1.88M |
| PP&E, net | $3,333 | $6,244 | $14,556 | $38,836 | $51,407 | $63,979 | $60,474 | $73,046 |
| Intangibles | $2.08M | $2.08M | $2.09M | $2.09M | $2.09M | $2.09M | — | — |
| Total assets | $2.27M | $2.80M | $3.65M | $4.43M | $5.00M | $6.49M | $89,093 | $1.96M |
| Current liabilities | $1.15M | $1.07M | $1.03M | $6.82M | $9.70M | $10.46M | $5.04M | $942,759 |
| Total liabilities | $1.15M | $1.07M | $1.03M | $6.82M | $9.70M | $10.46M | $5.04M | $942,759 |
| Shareholders' equity | $1.12M | $1.72M | $2.62M | -$2.39M | -$4.70M | -$3.97M | -$4.95M | -$3.32M |
| Shares outstanding | 1.81M | 1.81M | 1.81M | 1.93M | 1.93M | 1.85M | 5.80M | 517,257 |
| Cash flow statement | ||||||||
| Operating cash flow | -$488,889 | -$944,298 | $265,533 | -$509,667 | -$1.40M | -$1.75M | -$1.07M | -$353,640 |
| Investing cash flow | — | — | -$313,297 | $0 | $0 | $943,180 | — | -$1.22M |
| Financing cash flow | — | — | -$533,898 | -$2 | -$15,405 | $5.01M | $102,519 | $1.37M |
| Depreciation & amortization | $2,911 | $8,312 | $11,501 | $12,572 | $12,572 | $12,571 | $12,572 | $0 |
| Stock-based compensation | $62,409 | $67,012 | $91,652 | $95,942 | $105,868 | $125,127 | $236,014 | $245,436 |
Free plan shows the latest 8 periods; Pro shows all 57 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.